Table 2.
Comparison of 11 plasma biomarkers between ARDS cases and controls in the derivation cohort
| Biomarker | ARDS (n=79) | No ARDS (n=318) | p Value |
| RAGE (pg/mL) | 1886 (956–3298) | 944 (646–1523) | <0.001 |
| PCPIII (ng/mL) | 3.9 (2.9–5.0) | 3.5 (2.7–4.8) | 0.251 |
| BNP (ng/mL) | 0.4 (0.3–0.7) | 0.4 (0.3–0.6) | 0.312 |
| Ang-2 (pg/mL) | 5880 (4429–7724) | 4007 (2763–5816) | <0.001 |
| IL-8 (pg/mL) | 15.6 (15.6–57.7) | 15.6 (15.6–34.9) | 0.017 |
| TNF-α (pg/mL) | 1.0 (0.6–3.0) | 1.4 (0.6–5.1) | 0.195 |
| IL-10 (pg/mL) | 18.2 (9.4–82.4) | 18.1 (8.1–56.7) | 0.373 |
| VWF (% control) | 230 (173–353) | 270 (198–364) | 0.045 |
| SP-D (ng/mL) | 60.3 (37.2–91.9) | 53.6 (32.9–78.4) | 0.061 |
| PAI-1 (ng/mL) | 118.9 (39.1–248.5) | 92.3 (50.6–174.5) | 0.476 |
| CC16 (ng/mL) | 7.0 (4.2–11.2) | 5.5 (3.4–8.6) | 0.004 |
Data as median (IQR). Ang-2, angiopoietin-2; BNP, brain natriuretic peptide; CC16, club cell-16 protein; IL-8, interleukin 8; IL-10; interleukin 10; PAI-1, plasminogen activator inhibitor-1; PCPIII, procollagen peptide-III; RAGE, receptor for advanced glycation endproducts; SP-D, surfactant protein-D; TNF-α, tumor necrosis factor-α; VWF, von Willebrand factor antigen.